Communicating Multiple Uncertainties Associated With the Benefits and Risks of New Cancer Drugs

Summary

This nationally representative randomized survey of US adults will evaluate the effect of using brief statements to communicate multiple different sources of uncertainties about the benefits and harms of new cancer drugs on participants' decisions.

Conditions

• Cancer

Interventions

OTHER

Statement communicating 1 source of uncertainty

It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova.

OTHER

Statements communicating 2 sources of uncertainties

It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova. Zenova has not been studied in patients similar to Alex (patients with her race and ethnicity). It is unknown whether Zenova will work and what harms it will have for patients like her.

OTHER

Statements communicating 3 sources of uncertainties

It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova. Zenova has not been studied in patients similar to Alex (patients with her race and ethnicity). It is unknown whether Zenova will work and what harms it will have for patients like her. Zenova has only been shown to shrink the size of tumors. It is unknown whether Zenova improves how patients feel or how long they live.

OTHER

Statements communicating 4 sources of uncertainties

It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova. Zenova has not been studied in patients similar to Alex (patients with her race and ethnicity). It is unknown whether Zenova will work and what harms it will have for patients like her. Zenova has only been shown to shrink the size of tumors. It is unknown whether Zenova improves how patients feel or how long they live. Since patients given Zenova were followed for a short time, the longer-term benefits and harms of taking Zenova are unknown.

OTHER

Control group

No information about uncertainty

Sponsors & Collaborators

• Harvard Medical School / Harvard Pilgrim Health Care Institute

  collaborator UNKNOWN

• London School of Economics and Political Science

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

TRIPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2025-07-18

Primary Completion

2025-07-26

Completion

2025-07-26

Countries

• United Kingdom

Study Locations